

## **abaloparatide (Tymlos)**

---

### **Drugs**

TYMLOS

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

2 years

### **Other Criteria**

## **Ambrisentan (Letairis)**

---

### **Drugs**

LETAIRIS

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

Pregnancy

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **apomorphine (Apokyn)**

---

### **Drugs**

APOKYN

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Apremilast (Otezla)**

---

### **Drugs**

OTEZLA, OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Aprepitant (Emend)**

---

### **Drugs**

*aprepitant*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

3 months

### **Other Criteria**

None

## **Dacomitinib (Vizimpro)**

---

### **Drugs**

VIZIMPRO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Dalfampridine (Ampyra)**

---

### **Drugs**

*dalfampridine*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Daptomycin (Cubicin)**

---

### **Drugs**

*daptomycin*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

Minimum of 2 weeks and may extend up to 6 weeks based on indication.

### **Other Criteria**



## **Darbepoetin (Aranesp)**

---

### **Drugs**

ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML, ARANESP (IN POLYSORBATE) INJECTION SYRINGE

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 months

### **Other Criteria**

## **Dextromethorphan/Quinidine (Nuedexta)**

---

### **Drugs**

NUEDEXTA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Diclofenac (Solaraze)**

---

### **Drugs**

*diclofenac sodium topical gel 3 %*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Diclofenac Epolamine (Flector)**

---

### **Drugs**

FLECTOR

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

2 weeks

### **Other Criteria**

## **Dimethyl Fumarate (Tecfidera)**

---

### **Drugs**

TECFIDERA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Dornase Alfa (Pulmozyme)**

---

### **Drugs**

PULMOZYME

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Droxidopa (Northera)**

---

### **Drugs**

NORTHERA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Dulaglutide (Trulicity)**

---

### **Drugs**

TRULICITY

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**



## **Duvelisib (Copiktra)**

---

### **Drugs**

COPIKTRA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Elbasvir and Grazoprevir (Zepatier)**

---

### **Drugs**

ZEPATIER

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12-16 weeks

### **Other Criteria**

Criteria will be applied consistent with current AASLD/IDSA guidance.

## **eltrombopag (Promacta)**

---

### **Drugs**

PROMACTA ORAL TABLET

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **epoetin (Epogen)**

---

### **Drugs**

EPOGEN INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, RETACRIT

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 months

### **Other Criteria**

## **Epoetin (Procrit)**

---

### **Drugs**

PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

bleeding, autoimmune hemolytic anemia, insufficient vitamin stores, uncontrolled HTN, cancer patients with radiation alone

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 months

### **Other Criteria**

## **Everolimus (Zortress)**

---

### **Drugs**

ZORTRESS

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Evolocumab (Repatha)**

---

### **Drugs**

REPATHA PUSHTRONEX, REPATHA SURECLICK, REPATHA SYRINGE

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Ezetimibe (Zetia)**

---

### **Drugs**

*ezetimibe*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**



## **Fentanyl Lozenge**

---

### **Drugs**

*fentanyl citrate*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Opioid tolerant

## **Fentanyl Transdermal Patch**

---

### **Drugs**

*fentanyl*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

Refractory or intolerant to oral pain management

## **Fidaxomicin (Dificid)**

---

### **Drugs**

DIFICID

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

10 days

### **Other Criteria**

## **Filgrastim (Neupogen)**

---

### **Drugs**

NIVESTYM, ZARXIO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

not for afebrile neutropenia

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 months

### **Other Criteria**

None

## **glecaprevir/pibrentasvir (Mavyret)**

---

### **Drugs**

MAVYRET

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 weeks

### **Other Criteria**

Criteria will be applied consistent with current AASLD/IDSA guidance

## **Golimumab (Simponi)**

---

### **Drugs**

SIMPONI

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **guselkumab (Tremfya)**

---

### **Drugs**

TREMFYA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Imiquimod (Aldara)**

---

### **Drugs**

*imiquimod*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

4 months

### **Other Criteria**



## **Interferon Beta 1A (Rebif, Avonex)**

---

### **Drugs**

AVONEX (WITH ALBUMIN), AVONEX INTRAMUSCULAR PEN INJECTOR KIT, AVONEX INTRAMUSCULAR SYRINGE KIT, REBIF (WITH ALBUMIN), REBIF REBIDOSE, REBIF TITRATION PACK

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

Neurologist

### **Coverage Duration**

3 months

### **Other Criteria**

## **Ivacaftor (Kalydeco)**

---

### **Drugs**

KALYDECO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Ledipasvir/Sofosbuvir (Harvoni)**

---

### **Drugs**

*ledipasvir-sofosbuvir*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 weeks in patients without cirrhosis, 24 weeks in patients with cirrhosis

### **Other Criteria**

## **Lenalidomide (Revlimid)**

---

### **Drugs**

REVLIMID

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

3 months

### **Other Criteria**

## **Levomilnacipran (Fetzima)**

---

### **Drugs**

FETZIMA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Linezolid (Zyvox)**

---

### **Drugs**

*linezolid, linezolid in dextrose 5%*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

28 days

### **Other Criteria**

## **Lomitapide Mesylate (Juxtapid)**

---

### **Drugs**

JUXTAPID

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Lorlatinib (Lorbrena)**

---

### **Drugs**

LORBRENA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**



## **Lubiprostone (Amitiza)**

---

### **Drugs**

AMITIZA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Lumacaftor/Ivacaftor (Orkambi)**

---

### **Drugs**

ORKAMBI

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Macitentan (Opsumit)**

---

### **Drugs**

OPSUMIT

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Megestrol**

---

### **Drugs**

*megestrol oral suspension 400 mg/10 ml (40 mg/ml)*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

Assess for weight gain after initial coverage duration

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 months

### **Other Criteria**

## **Methylnaltrexone (Relistor)**

---

### **Drugs**

RELISTOR ORAL, RELISTOR SUBCUTANEOUS SOLUTION, RELISTOR SUBCUTANEOUS SYRINGE

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Mipomersen Sodium (Kynamro)**

---

### **Drugs**

KYNAMRO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Modafanil (Provigil)**

---

### **Drugs**

*modafinil*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

None

## **Nintedanib Esylate (Ofev)**

---

### **Drugs** OFEV

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**



## **Parathyroid Hormone (Natpara)**

---

### **Drugs**

NATPARA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Pimavanserin tartrate (Nuplazid)**

---

### **Drugs**

NUPLAZID

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Pirfenidone (Esbriet)**

---

### **Drugs**

ESBRIET

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Pomalidomide (Pomalyst)**

---

### **Drugs**

POMALYST

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

3 months

### **Other Criteria**

## **Quinine Sulfate**

---

### **Drugs**

*quinine sulfate*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

1 week

### **Other Criteria**

## **Ribavirin Oral**

---

### **Drugs**

REBETOL ORAL SOLUTION, *ribavirin oral capsule, ribavirin oral tablet 200 mg*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

3 months

### **Other Criteria**

## **Rifaximin (Xifaxan)**

---

### **Drugs**

XIFAXAN ORAL TABLET 200 MG

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

3 days

### **Other Criteria**

## **Riociguat (Adempas)**

---

### **Drugs**

ADEMPAS

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**



## **Roflumilast (Daliresp)**

---

### **Drugs**

DALIRESP

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Rotigotine (Neupro)**

---

### **Drugs**

NEUPRO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Sacubitril/Valsartan (Entresto)**

---

### **Drugs**

ENTRESTO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

**sargramostim (Leukine)**

---

**Drugs**

LEUKINE INJECTION RECON SOLN

**Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

**Exclusion Criteria**

**Required Medical Information**

**Age Restriction**

**Prescriber Restriction**

**Coverage Duration**

2 months

**Other Criteria**

## **Selegilene transdermal**

---

### **Drugs**

EMSAM

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## Selexipag (Uptravi)

---

### **Drugs**

UPTRAVI

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Sildenafil Citrate (Revatio)**

---

### **Drugs**

*sildenafil (antihypertensive) oral*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Sirolimus (Rapamune)**

---

### **Drugs**

RAPAMUNE ORAL SOLUTION, *sirolimus*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**



## **Sofosbuvir (Solvaldi)**

---

### **Drugs**

SOVALDI

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12, 16, 24 or 48 weeks

### **Other Criteria**

Consider genotype, cirrhosis status, previous failure of PEG-IFN/RBV/protease inhibitors/sofosbuvir, HCV in an allograft, decompensated cirrhosis, if awaiting transplant and concurrent treatment

## **Sofosbuvir and Velpatasvir (Epclusa)**

---

### **Drugs**

EPCLUSA, *sofosbuvir-velpatasvir*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 weeks

### **Other Criteria**

Criteria will be applied consistent with current AASLD/IDSA guidance

## **sofosbuvir/velpatasvir/voxilaprevir (Vosevi)**

---

### **Drugs**

VOSEVI

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 weeks

### **Other Criteria**

Criteria will be applied consistent with current AASLD/IDSA guidance

## Somatropin

---

### **Drugs**

GENOTROPIN, GENOTROPIN MINIQUICK, HUMATROPE, NORDITROPIN FLEXPRO, NUTROPIN AQ NUSPIN, OMNITROPE, SAIZEN, SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG, ZORBTIVE

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Tacrolimus (Prograf)**

---

### **Drugs**

ASTAGRAF XL, ENVARSUS XR, *tacrolimus oral*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Tadalafil (Adcirca)**

---

### **Drugs**

ADCIRCA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Tasimelteon (Hetlioz)**

---

### **Drugs**

HETLIOZ

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Tedizolid Phosphate (Sivextro)**

---

### **Drugs**

SIVEXTRO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

6 days

### **Other Criteria**



## **Teriflunomide (Aubagio)**

---

### **Drugs**

AUBAGIO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

1 year

### **Other Criteria**

## **Teriparatide (Forteo)**

---

### **Drugs**

FORTEO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

2 years

### **Other Criteria**

None

## **tetrahydrocannabinol**

---

### **Drugs**

*dronabinol*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **tezacaftor/ivacaftor and ivacaftor (Symdeko)**

---

### **Drugs**

SYMDEKO

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D.

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Ticagrelor (Brilinta)**

---

### **Drugs**

BRILINTA

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Tigecycline (Tygacil)**

---

### **Drugs**

*tigecycline*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

14 days

### **Other Criteria**

## **Tofacitinib Citrate (Xeljanz)**

---

### **Drugs**

XELJANZ, XELJANZ XR

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Vancomycin Oral Solution**

---

### **Drugs**

*vancomycin oral capsule*

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

2 weeks

### **Other Criteria**

None



## **Varenicline (Chantix)**

---

### **Drugs**

CHANTIX, CHANTIX CONTINUING MONTH BOX, CHANTIX STARTING MONTH BOX

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 weeks and may extend up to 24 weeks if have stopped smoking after initial 12 weeks of therapy.

### **Other Criteria**

None

## **Vilazodone (Viibryd)**

---

### **Drugs**

VIIBRYD ORAL TABLET, VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23)

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

## **Vortioxetine (Trintellix)**

---

### **Drugs**

TRINTELLIX

### **Covered Uses**

All FDA-approved indications not otherwise excluded from Part D

### **Exclusion Criteria**

### **Required Medical Information**

### **Age Restriction**

### **Prescriber Restriction**

### **Coverage Duration**

12 months

### **Other Criteria**

